GlassScriptPhysician profile
Laura D Carnevale
NPI 1962617159
$2,749.84
in general payments reported to CMS, 2019-2025
22 companies · $1,042 in 2025
The $1,042 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,048 · 2022: $152 · 2023: $403 · 2024: $105 · 2025: $1,042.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,549.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $746.28 | 2021-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $530.74 | 2021-2025 | Breztri, Tezspire, Fasenra |
| Electromed, INC. | $209.23 | 2022-2025 | Smartvest |
| Verona Pharma, INC. | $205.73 | 2025 | Ohtuvayre |
| Lilly USA, LLC | $187.64 | 2022-2025 | Zepbound |
| Harmony Biosciences LLC | $143.63 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $124.85 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.43 | 2021 | |
| Idorsia Pharmaceuticals US INC | $78.59 | 2023 | Quviviq |
| Genzyme Corporation | $66.79 | 2021-2025 | |
| Grifols USA, LLC | $58.87 | 2021-2025 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $49.01 | 2024-2025 | Glassia |
| Jazz Pharmaceuticals INC. | $39.18 | 2021 | |
| Mylan Specialty L.P. | $37.35 | 2022-2024 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $35.67 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $27.69 | 2021 | |
| Travere Therapeutics, INC. | $25.57 | 2023 | |
| Amgen INC. | $25.18 | 2021 | |
| Boston Scientific Corporation | $22.89 | 2023 | Watchman Access System |
| Novo Nordisk INC | $18.90 | 2025 | Ozempic |
| Regeneron Healthcare Solutions, INC. | $18.85 | 2021 | |
| Philips North America LLC | $15.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Carnevale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.